

1 **The Effect of Incarceration on Tuberculosis Treatment Outcomes in Brazil: a**
2 **Retrospective Cohort Study**

3

4

5 Jamieson O'Marr¹, Crhistinne Gonçalves², Denise Arakaki-Sanchez³, Daniele Maria Pelissari
6 PhD³, Fernanda Dockhorn Costa³, Julio Croda^{2,4,5*}, Katharine S. Walter^{6*}, Jason R. Andrews^{6*}

7

8 1. Yale School of Medicine, New Haven, CT, USA

9 2. Federal University of Mato Grosso do Sul, School of Medicine, Campo Grande, MS, Brazil

10 3. National Tuberculosis Control Program, Brasília, DF, Brazil

11 4. Oswaldo Cruz Foundation, Public Health, Campo Grande, MS, Brazil

12 5. Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New
13 Haven, CT, USA

14 6. Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA

15 *Contributed equally

16

17

18 Running Head: Incarceration and TB outcomes in Brazil

19

20

21 Article Word Count: 2491

22 No. of references: 27

23 No. of Tables: 3

24 No of Figures: 2

25

26

27 Keywords: tuberculosis; incarceration; treatment outcomes; DOTS

28

29

30 Correspondence:

31 Jamieson O'Marr

32 Yale School of Medicine

33 333 Cedar St

34 New Haven CT, USA, 06510

35 Email: jamiesonomarr@gmail.com

36

37

38

39 **Abstract**

40

41 **Background:** Tuberculosis notifications in Latin American prisons have more than doubled over
42 the past two decades; however, treatment outcomes and their determinants among incarcerated
43 individuals in this region are not well understood.

44

45 **Methods:** Newly diagnosed drug-susceptible tuberculosis cases reported to Brazil's Sistema de
46 Informação de Agravos de Notificação (SINAN) between January 2015 and December 2017
47 were included. Multivariate logistic regression was used to assess socioeconomic and clinical
48 factors associated with treatment success among incarcerated individuals.

49

50 **Results:** Incarcerated individuals (n=17,776) had greater treatment success than non-incarcerated
51 individuals (n=160,728; 82.2% vs 75.1%, $p<0.0001$), including after adjusting for demographic
52 and clinical risk factors (adjusted Odds Ratio [aOR]: 1.27; 95% CI: 1.19-1.34). These differences
53 were partially mediated by increased use of directly observed therapy among incarcerated
54 individuals (DOT) (61% vs 47%, $p<0.001$), which was associated with greater efficacy in the
55 incarcerated population (aOR 2.56 vs aOR 2.17; $p<0.001$). DOT was associated with improved
56 treatment success among incarcerated subpopulations at elevated risk of poor outcomes.

57

58 **Conclusion:** Tuberculosis treatment success among incarcerated individuals in Brazil is higher
59 than non-incarcerated individuals, but both fall below WHO targets. Expanding the use of DOT
60 and services for socially and medically vulnerable individuals may improve outcomes in carceral
61 settings.

62

63 **Article**

64 **INTRODUCTION**

65 Tuberculosis remains one of the leading causes of death by an infectious disease. In 2019,
66 there were an estimated 10 million cases with approximately 1.2 million deaths among HIV-
67 negative individuals and an additional 250,000 deaths among HIV co-infected individuals¹. The
68 World Health Organization (WHO) has identified 30 countries with the highest burden of
69 tuberculosis, where 87% of the world's new tuberculosis cases occurred in 2019¹. Brazil remains
70 the only country within the Americas within this group.

71 The incidence of tuberculosis in Brazil has slowly declined over the last 20 years,
72 although in the last three years there has been a modest increase². This trend has been part of a
73 troubling rise in tuberculosis cases across Central and South America in recent years³. The rate
74 of incarceration in Central and South America has increased more than 206% since 2000 while
75 tuberculosis cases among incarcerated individuals have increased by an even larger amount³⁻⁷.
76 Incarcerated individuals represent a disproportionate and growing proportion of the total
77 tuberculosis cases across Central and South America. The higher prevalence of HIV, smoking,
78 alcohol and illicit drug use among incarcerated populations, together with increased risk of
79 infection and deficiencies in health facilities, pose threats to the successful treatment of
80 tuberculosis in correctional settings^{4,8,9}.

81 There are few published studies examining tuberculosis treatment outcomes in
82 correctional facilities in the Americas, and the factors associated with poor outcomes in these
83 settings are not well understood. Understanding these factors well and addressing them will be
84 important for controlling tuberculosis both within incarcerated populations and surrounding

85 communities. We used Brazil's national tuberculosis registry to measure the effect of
86 incarceration on tuberculosis treatment outcomes and identify risk factors for lack of tuberculosis
87 treatment success among Brazil's growing incarcerated population.

88

89 **METHODS**

90 *Study Design and Participants*

91 We conducted a retrospective cohort study of tuberculosis cases reported to Brazil's
92 national notifiable disease system, Sistema de Informação de Agravos de Notificação (SINAN),
93 from January 2015 through December 2017. All individuals diagnosed with tuberculosis in
94 Brazil are mandatorily reported to SINAN^{10,11}. SINAN reports tuberculosis treatment outcome at
95 the completion of treatment as cure, lost to follow-up, death from tuberculosis, death from other
96 causes, transfer, diagnostic change, drug-resistant tuberculosis, change in treatment regimen, and
97 therapeutic failure.

98 We excluded patients with a change in diagnosis and those who did not have a reported
99 treatment outcome. Patients who were found to have multidrug-resistant tuberculosis (MDR-TB)
100 cases at diagnosis were also excluded because MDR-TB treatment outcomes are reported in a
101 separate database. MDR-TB cases were defined as those individuals whose *M. tuberculosis*
102 isolate was resistant to isoniazid and rifampin at the time of diagnosis. Additionally, we excluded
103 cases without a reported incarceration status and limited our analysis to only new identified
104 tuberculosis cases due to differing treatment outcome definitions among retreatment tuberculosis
105 cases. Race is a self-reported variable within SINAN with five established survey categories:
106 black, brown or mixed race, white, Asian, and indigenous.

107

108 *Outcomes and Definitions*

109 We defined treatment success as cases reported as “cure” in SINAN. The Brazilian
110 National Tuberculosis Program defines cure as two negative sputum smears at the end of therapy
111 or the completion of treatment with no evidence of failure and clinical and radiological criteria in
112 individuals without a sputum smear test. In our models, we defined lack of treatment success as
113 lost to follow-up, death due to tuberculosis, death due to other causes, therapeutic failure
114 (including MDR diagnosis after treatment), or transfer. We included all newly reported
115 tuberculosis cases among people above the age of 18 at diagnosis with complete information for
116 incarceration status and treatment outcome.

117 In addition to the treatment outcome, the following variables were extracted from
118 SINAN: 1) incarceration status at the time of tuberculosis notification, 2) sex, 3) age at
119 diagnosis, 4) year of diagnosis, 5) self-reported race, 6) education level, 7) received directly
120 observed therapy (at least 3 weekly assisted doses throughout the treatment course), 8) alcohol
121 use disorder, 9) HIV status, 10) diabetes status, 11) presence of a mental health condition, 12)
122 clinical form of tuberculosis 13) Brazilian state of diagnosis. The clinical variables of alcohol use
123 disorder, diabetes, and presence of a mental health condition are determined and reported by the
124 healthcare worker notifying the case to SINAN at the time of diagnosis.

125

126 *Statistical Analysis*

127 Data analysis was conducted in R (version 3.5.3) and R Studio (version 1.2.1335).
128 Missingness was under 10% for the majority of the variables included in our analysis and
129 covariates with missingness greater than 30% were excluded. To address missingness in

130 measured covariates, we employed multiple imputation for race, education level, directly
131 observed therapy (DOT), HIV status, alcohol use disorder, diabetes, and the presence of a mental
132 health condition using the mice package in R^{12,13}.

133 We compared our outcomes and extracted demographic and clinical variables between
134 the non-incarcerated and incarcerated population with chi-squared statistics. We tested the effect
135 of clinical and sociodemographic variables on tuberculosis treatment outcome with mixed effects
136 multivariable logistic regression including incarceration status, DOT, sex, self-reported race, age
137 strata, year of diagnosis, education level, HIV status, alcohol use disorder, diabetes, mental
138 health condition, and form of tuberculosis with state included as a random effect. These variables
139 were selected based on previous studies and subject level knowledge of factors that affect
140 tuberculosis treatment outcomes. We included a multiplicative interaction between DOT and
141 incarceration to assess for any relationship between these two variables. Odds ratios with 95%
142 confidence intervals were reported. To investigate the relationship between the predictors in the
143 above model more specifically among the incarcerated population, a multivariable logistic
144 regression was employed.

145

146 *Ethics Statement*

147 This study was approved by the IRB at Stanford University (Protocol #50466) and the IRB at the
148 Universidade Federal Do Mato Grosso Do Sul (Protocol #20531819.5.0000.0021).

149

150 **RESULTS**

151 A total of 178,504 new tuberculosis cases were reported to Brazil's national tuberculosis
152 registry between 2015 and 2017. Among those, 17,776 (9.96%) individuals were incarcerated at

153 the time of diagnosis. The overwhelming majority of cases notified in the incarcerated
154 population occurred among men (96.4%), compared to 66.2% of cases notified in the general
155 population (χ^2 test, $p < 0.0001$). The proportion of individuals with tuberculosis who were HIV
156 co-infected was lower among the incarcerated population than the general population (6.4% vs
157 11.1%; $p < 0.0001$), as was the percentage of patients with reported alcohol use disorder (12.7%
158 vs 18.6%, $p < 0.001$). Incarcerated individuals were younger (30.4 vs 42.7 years, $p < 0.0001$) and
159 were more likely to be treated under DOT than non-incarcerated individuals (61.0% vs 47.4%,
160 $p < 0.0001$).

161 135,238 (75.8%) were considered to have treatment success, 18,261 (10.2%) lost to
162 follow-up, 5,714 (3.2%) died of tuberculosis, 8,175 (4.6%) died by other causes, 9,254 (5.2%)
163 transferred from the program, 730 (0.4%) were subsequently diagnosed with drug-resistant
164 tuberculosis after a trial of therapy, 1,012 (0.6%) changed treatment regimen, and 120 (0.07%)
165 experienced therapeutic failure. Treatment success was higher among incarcerated individuals
166 compared with the general population (82.2% vs 75.1%, $p < .0001$). Notable differences in the
167 remaining treatment outcomes between the incarcerated and non-incarcerated populations was a
168 lower rate of death by tuberculosis (0.9% vs 3.5%; $p < 0.0001$), death by other causes (1.3% vs
169 4.9%; $p < .0001$) and lost to follow-up (8.5% vs 10.4%; $p < 0.0001$).

170 In a multivariable model, incarceration at the time of tuberculosis notification was
171 associated with an increased odds of treatment success (Table 2; aOR: 1.26; 95% CI: 1.19-1.34).
172 DOT was also strongly associated with treatment success (aOR: 2.16; 95% CI: 2.11-2.22). We
173 also found a significant interaction between incarceration and DOT (aOR: 1.18; 95% CI: 1.09-
174 1.28), suggesting that DOT has a greater positive impact on treatment success among the
175 incarcerated population compared to the general population. Factors that were negatively

176 associated with treatment success in the entire cohort included HIV co-infection (aOR: 0.33;
177 95% CI: 0.32-0.34), reported alcohol use disorder (aOR: 0.55; 95% CI: 0.54-0.57), age greater
178 than 65 years (aOR: 0.71; 95% CI: 0.68-0.75) and self-reported non-white race (black, aOR:
179 0.80; 95% CI 0.75-0.84; mixed race, aOR: 0.81; 95% CI: 0.79-0.84; Asian, aOR: 0.83; 95% CI:
180 0.73-0.94).

181 In a multivariable model among only incarcerated individuals, DOT (Table 3; aOR: 2.50;
182 95% CI: 2.31-2.71) and having completed a high school education (aOR: 1.77; 95% CI: 1.58-
183 1.97) were positively associated with treatment success. We additionally identified several
184 factors associated with lower treatment success within this population. These included a non-
185 white race (black, aOR: 0.83; 95% CI: 0.72-0.94; mixed race, aOR: 0.75; 95% CI: 0.69-0.82;
186 indigenous, aOR: 0.49; 95% CI 0.29-0.82), HIV infection (aOR: 0.39; 95% CI: 0.34-0.45),
187 reported alcohol use disorder (aOR: 0.63; 95% CI: 0.57-0.70), a diagnosed mental health
188 condition (aOR: 0.60; 95% CI: 0.46-0.80), and being over the age of 65 (aOR: 0.46; 95% CI:
189 0.33-0.65).

190 Using predicted probabilities from our multivariable model among incarcerated
191 individuals, we demonstrate that DOT was associated with increased treatment success across a
192 number of important predictors including age, self-reported race, sex, alcohol use disorder,
193 education level, and HIV status (Figure 1). Individuals with risk factors associated with lower
194 probability of treatment success had substantially improved outcomes when treated with DOT,
195 with most subpopulations having an estimated treatment success probability above 85%. Use of
196 DOT among incarcerated populations varied substantially across Brazil, ranging from 0% of
197 incarcerated patients uncovered by DOT in the state of Amapá (n = 47) to as many as 89% of
198 incarcerated patients not utilizing DOT in the state of Rondônia (n = 238) (Figure 2). In total, 8

199 out of Brazil's 27 states had over half of their incarcerated population not using DOT, leaving
200 the national average DOT coverage among incarcerated patients at 61%. The states with the
201 largest population of incarcerated individuals not utilizing DOT during tuberculosis treatment
202 were São Paulo (n=2,589), Rio Grande do Sul (n=946), and Rio de Janeiro (n=658).

203

204

205 **DISCUSSION**

206 Tuberculosis notifications have been rising steeply in prisons in Latin America, largely
207 driven by increasing rates of incarceration³. However, the impact of incarceration on tuberculosis
208 treatment outcomes and risk factors for treatment failure within prisons have only begun to be
209 identified. Drawing upon Brazil's national tuberculosis notification system, we found that
210 incarceration at the time of tuberculosis diagnosis was associated with higher rates of treatment
211 success compared with the general population. Use of DOT was greater in prisons than the
212 community and was the strongest predictor of tuberculosis treatment success among incarcerated
213 individuals. However, the proportion of individuals achieving treatment success in prisons (82%)
214 and the general population (75%) do not meet the World Health Organization's END-TB
215 Strategy 2025 target of 90% treatment success¹. Among incarcerated individuals, we identified
216 several risk factors and demographic groups in whom treatment outcomes are particularly poor
217 which could inform the development of targeted services and interventions to reduce disparities
218 and improve outcomes.

219 Our study explored DOT and its relationship to overall treatment success, finding that
220 DOT is strongly associated with better treatment outcomes for all tuberculosis patients. Our
221 analysis also explored the interaction between DOT and incarceration status and demonstrated a
222 significant positive interaction, which underscores the particular importance of DOT for the
223 incarcerated population. Previous literature surrounding DOT has shown mixed efficacy¹³,
224 particularly in correctional settings, however our findings add to the work by Macedo et al. and
225 others which demonstrate a similar beneficial effect of DOT on treatment outcomes among
226 incarcerated individuals in Brazil¹⁴⁻¹⁶. The usage of DOT within the carceral setting poses
227 unique challenges; however, the observed ability of certain states to employ DOT among nearly

228 all incarcerated tuberculosis patients indicate that it is possible. The skills and strategies for the
229 effective employment of DOT therapy require further study as it has the potential to improve
230 population-level tuberculosis treatment outcomes within Brazilian prisons and in the general
231 population.

232 Our finding of increased odds of treatment success with incarceration is consistent with
233 previous studies of incarcerated individuals. These studies demonstrate that diagnosing and
234 treating tuberculosis during incarceration, and other infectious diseases such as HIV, may, in
235 some circumstances, improve treatment outcomes due to increased access to medical care during
236 incarceration amongst populations systematically excluded from care^{17,22}. However, these studies
237 also find that transitions of care, such as the kinds that result from transfer within a penal system
238 or release, often result in poorer overall outcomes in incarcerated individuals^{17,19–22}. Further
239 studies are needed to investigate outcomes of tuberculosis treatment among individuals who are
240 receiving therapy at the time of release from prison.

241 Previous studies have identified racial disparities in tuberculosis treatment outcomes in
242 the general population in Brazil.^{8,23,25} We found that such disparities also exist among
243 incarcerated individuals. Adjusting for multiple other demographic and clinical attributes, black
244 incarcerated individuals had nearly 20% lower adjusted odds of treatment success than white
245 incarcerated individuals. Whether this disparity is due to delays in diagnoses, differences in
246 treatment or other factors is not clear from the available data, and further studies are needed to
247 understand the determinants of these disparities so that they can be effectively addressed.

248 Additional factors that were associated with worse outcomes were alcohol use disorder
249 and HIV positive status, both of which are well-documented predictors for poor treatment
250 outcomes¹⁴. Finally, other studies have identified the importance of social, educational, and

251 economic support with improved tuberculosis treatment outcomes, something our proxy of
252 education level also supports^{17,19}.

253 While we investigated a large, quality-controlled national tuberculosis registry, our
254 findings have several limitations. First, Brazil's tuberculosis registry had varying levels of data
255 missingness for several variables. Certain important covariates for treatment success, such as
256 smoking, were missing in more than half of notified cases and had to be excluded. For covariates
257 with less than 30% of observations missing, we used multiple imputation to handle missingness.
258 Another limitation was the lack of standardized screens for clinical covariates such as diabetes,
259 mental health disease, and alcohol use disorder. These determinations were made at the time of
260 diagnosis and thus could be susceptible to bias and underdiagnosis—potentially substantially.
261 Additionally, SINAN lacks economic indicators, limiting us to only education as a social
262 indicator. Due to significant reporting changes in the national tuberculosis registry made in 2015,
263 we could only examine cases from 2015 through 2017. While drug-resistant tuberculosis
264 epidemics in prisons have posed major challenges in many parts of the world, in Brazil, <0.4%
265 of tuberculosis cases in our study were multidrug-resistant which concurs with previous findings
266 by Macedo et al.¹⁴. Nevertheless, further studies are needed to characterize risk factors for
267 treatment success for multi-drug resistant tuberculosis in correctional settings in Brazil. Despite
268 these limitations, our study utilized a large national surveillance system that enabled a robust
269 evaluation of the covariates associated with treatment success in Brazilian prisons.

270 There is an urgent need to identify robust strategies for prompt diagnosis and effective
271 treatment to address the increasing burden of tuberculosis in prisons in Brazil and across the
272 Americas. While treatment success rates in prisons exceed those of the general population in
273 Brazil, there remains substantial room for improvement, particularly among vulnerable

274 incarcerated populations. Our findings suggest that tuberculosis treatment success can be
275 improved through expanding the use of DOT, particularly for incarcerated sub-populations at the
276 highest risk of poor outcomes.

277

278

279 **References**

- 280 1. World Health Organization. Global Tuberculosis Report 2020. 2020.
- 281 2. World Health Organization. Tuberculosis Profile: Brazil [Internet]. Available from:
282 [https://worldhealthorg.shinyapps.io/tb_profiles/?_inputs_&lan=%22EN%22&iso2=%22BR](https://worldhealthorg.shinyapps.io/tb_profiles/?_inputs_&lan=%22EN%22&iso2=%22BR%22&main_tabs=%22est_tab%22)
283 [%22&main_tabs=%22est_tab%22](https://worldhealthorg.shinyapps.io/tb_profiles/?_inputs_&lan=%22EN%22&iso2=%22BR%22&main_tabs=%22est_tab%22)
- 284 3. Walter KS, Martinez L, Arakaki-Sanchez D, Sequera VG, Estigarribia Sanabria G, Cohen T, et
285 al. The escalating tuberculosis crisis in central and South American prisons. *The Lancet*.
286 2021 Apr;S0140673620325782.
- 287 4. Carbone A da SS, Paião DSG, Sgarbi RVE, Lemos EF, Cazanti RF, Ota MM, et al. Active and
288 latent tuberculosis in Brazilian correctional facilities: a cross-sectional study. *BMC Infect*
289 *Dis*. 2015 Dec;15(1):24.
- 290 5. Bourdillon PM, Gonçalves CCM, Pelissari DM, Arakaki-Sanchez D, Ko AI, Croda J, et al.
291 Increase in Tuberculosis Cases among Prisoners, Brazil, 2009–20141. *Emerging Infectious*
292 *Diseases*. 2017 Mar;23(3):496–9.
- 293 6. Paião DSG, Lemos EF, Carbone A da SS, Sgarbi RVE, Junior AL, da Silva FM, et al. Impact of
294 mass-screening on tuberculosis incidence in a prospective cohort of Brazilian prisoners.
295 *BMC Infect Dis*. 2016 Dec;16(1):533.
- 296 7. Broach S, Petrone M, Ryan J, Sivram A. Reservoirs of Injustice: How incarceration for drug-
297 related offenses fuels the spread of tuberculosis in Brazil.
- 298 8. Basu S, Stuckler D, McKee M. Addressing Institutional Amplifiers in the Dynamics and
299 Control of Tuberculosis Epidemics. *The American Journal of Tropical Medicine and*
300 *Hygiene*. 2011 Jan 5;84(1):30–7.
- 301 9. Sánchez A, Huber FD, Massari V, Barreto A, Camacho LAB, Cesconi V, et al. Extensive
302 *Mycobacterium tuberculosis* circulation in a highly endemic prison and the need for urgent
303 environmental interventions. *Epidemiol Infect*. 2012 Oct;140(10):1853–61.
- 304 10. Brasil Ministério da Saúde. Manual de Recomendações para o Controle da Tuberculose no
305 Brasil. 2019;366.
- 306 11. Silva GDM da, Bartholomay P, Cruz OG, Garcia LP. Avaliação da qualidade dos dados,
307 oportunidade e aceitabilidade da vigilância da tuberculose nas microrregiões do Brasil.
308 *Ciênc saúde coletiva*. 2017 Oct;22(10):3307–19.
- 309 12. Buuren S van, Groothuis-Oudshoorn K. MICE: Multivariate Imputation by Chained Equations
310 in R. *J Stat Soft* [Internet]. 2011 [cited 2020 Jul 20];45(3). Available from:
311 <http://www.jstatsoft.org/v45/i03/>

- 312 13. Karumbi J, Garner P. Directly observed therapy for treating tuberculosis. Cochrane
313 Infectious Diseases Group, editor. Cochrane Database of Systematic Reviews [Internet].
314 2015 May 29 [cited 2021 Jul 20]; Available from:
315 <https://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003343.pub4>
- 316 14. Macedo LR, Reis-Santos B, Riley LW, Maciel EL. Treatment outcomes of tuberculosis
317 patients in Brazilian prisons: a polytomous regression analysis. 2013;9.
- 318 15. Macedo LR, Maciel ELN, Struchiner CJ. Factors associated with tuberculosis in persons
319 deprived of liberty in Espírito Santo. 2020;12.
- 320 16. Prado TN do, Rajan JV, Miranda AE, Dias E dos S, Cosme LB, Possuelo LG, et al. Clinical and
321 epidemiological characteristics associated with unfavorable tuberculosis treatment
322 outcomes in TB-HIV co-infected patients in Brazil: a hierarchical polytomous analysis. The
323 Brazilian Journal of Infectious Diseases. 2017 Mar;21(2):162–70.
- 324 17. Baillargeon J. Accessing Antiretroviral Therapy Following Release From Prison. JAMA. 2009
325 Feb 25;301(8):848.
- 326 18. Singano V, Kip E, Ching'ani W, Chiwaula L. Tuberculosis treatment outcomes among
327 prisoners and general population in Zomba, Malawi. BMC Public Health. 2020
328 Dec;20(1):700.
- 329 19. Palepu A, Tyndall MW, Chan K, Wood E, Montaner JS, Hogg RS. Initiating highly active
330 antiretroviral therapy and continuity of HIV care: the impact of incarceration and prison
331 release on adherence and HIV treatment outcomes. :8.
- 332 20. Mabud TS, de Lourdes Delgado Alves M, Ko AI, Basu S, Walter KS, Cohen T, et al. Evaluating
333 strategies for control of tuberculosis in prisons and prevention of spillover into
334 communities: An observational and modeling study from Brazil. Metcalfe JZ, editor. PLoS
335 Med. 2019 Jan 24;16(1):e1002737.
- 336 21. Schwitters A, Kaggwa M, Omiel P, Nagadya G, Kisa N, Dalal S. Tuberculosis incidence and
337 treatment completion among Ugandan prison inmates. 2016;11.
- 338 22. Adane K. Tuberculosis treatment outcome and predictors in northern Ethiopian prisons: a
339 five-year retrospective analysis. 2018;8.
- 340 23. Eshetie S, Gizachew M, Alebel A, van Soolingen D. Tuberculosis treatment outcomes in
341 Ethiopia from 2003 to 2016, and impact of HIV co-infection and prior drug exposure: A
342 systematic review and meta-analysis. Subbian S, editor. PLoS ONE. 2018 Mar
343 19;13(3):e0194675.
- 344 24. Thomas BE, Thiruvengadam K, S. R, Kadam D, Ovung S, Sivakumar S, et al. Smoking, alcohol
345 use disorder and tuberculosis treatment outcomes: A dual co-morbidity burden that
346 cannot be ignored. Glantz SA, editor. PLoS ONE. 2019 Jul 31;14(7):e0220507.

- 347 25. Ali MK, Karanja S, Karama M. Factors associated with tuberculosis treatment outcomes
348 among tuberculosis patients attending tuberculosis treatment centres in 2016-2017 in
349 Mogadishu, Somalia. 2018;14.
- 350 26. Andrade KVF de, Nery JS, Souza RA de, Pereira SM. Effects of social protection on
351 tuberculosis treatment outcomes in low or middle-income and in high-burden countries:
352 systematic review and meta-analysis. *Cad Saúde Pública* [Internet]. 2018 Feb 5 [cited 2020
353 Dec 14];34(1). Available from:
354 [http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0102-](http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0102-311X2018000102001&lng=en&tlng=en)
355 [311X2018000102001&lng=en&tlng=en](http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0102-311X2018000102001&lng=en&tlng=en)
- 356 27. Durovni B, Saraceni V, Puppini MS, Tassinari W, Cruz OG, Cavalcante S, et al. The impact of
357 the Brazilian Family Health Strategy and the conditional cash transfer on tuberculosis
358 treatment outcomes in Rio de Janeiro: an individual-level analysis of secondary data.
359 *Journal of Public Health*. 2018 Sep 1;40(3):e359–66.
- 360
361
362

363 **Table 1.** Sociodemographic and clinical characteristics of new Brazilian TB patients from 2015-
364 2017 after imputation, by incarceration status.

	Cohort		P value
	Non-Incarcerated (%) (N = 160728)	Incarcerated (%) (N = 17776)	
Sex			< .001
Men	106516 (66.2)	17134 (96.4)	
Women	54212 (33.8)	642 (3.4)	
Mean age (years)	42.7	30.4	< .001
18-25	27793 (17.3)	6809 (38.3)	< .001
26-45	66979 (41.7)	9753 (54.9)	
46-65	49552 (30.8)	1041 (5.8)	
> 65	16404 (10.2)	173 (1.0)	
Self-Reported Race			< .001
white	56680 (35.3)	6250 (35.2)	
black	21341 (13.2)	2171 (12.2)	
Asian	1297 (0.8)	164 (0.9)	
brown/mixed Race	79662 (49.6)	9103 (51.2)	
indigenous	1740 (1.1)	88 (0.5)	
Education (years)			< .001
Less than 5th Grade	48222 (30.0)	4439 (25.0)	
5th - 8th Completed	49177 (30.5)	8400 (47.3)	
Greater than 8th Completed	63318 (39.5)	4937 (27.7)	
Directly Observed Therapy	76124 (47.4)	10844 (61.0)	< .001
Comorbidities			
Alcohol Use Disorder	29836 (18.6)	2265 (12.7)	< .001
HIV Positive	17918 (11.1)	1145 (6.4)	< .001
Diabetes	14838 (9.2)	304 (1.7)	< .001
Mental Health Condition	4141 (2.6)	276 (1.5)	< .001
Tuberculosis Form			< .001
Pulmonary	132705 (82.6)	16921 (95.1)	
Extrapulmonary	22834 (14.2)	667 (3.8)	
Extrapulmonary and Pulmonary	5189 (3.2)	188 (1.1)	
Treatment Outcome			< .001
Cure	120632 (75.1)	14606 (82.2)	
Lost to Follow-up	16748 (10.4)	1513 (8.5)	
Death by TB	5553 (3.5)	161 (0.9)	
Death by Other Cause	7946 (4.9)	229 (1.3)	
Transfer	8045 (5.0)	1169 (6.6)	
MDR-TB	661 (0.4)	69 (0.4)	
Change in Treatment regimen	986 (0.6)	26 (0.1)	
Therapeutic Failure	117 (0.1)	3 (0.02)	

365 **Table 2.** Adjusted odds ratios for treatment success among all newly diagnosed tuberculosis
 366 cases using mixed-effects multivariable regression.

	aOR ¹	95% CI
Incarceration	1.27	1.19 - 1.34
Directly Observed Therapy (DOT)	2.17	2.11 - 2.22
Incarceration*DOT ²	1.18	1.08 - 1.28
Male sex	0.83	0.81 - 0.85
Age, years		
18-25	Ref	Ref
26-45	1.12	1.08 - 1.16
46-65	1.19	1.15 - 1.24
> 65	0.71	0.68 - 0.75
Self-Identified Race		
white	Ref	Ref
black	0.80	0.75 - 0.84
Asian	0.83	0.73 - 0.94
brown/mixed Race	0.81	0.79 - 0.84
indigenous	0.96	0.85 - 1.09
Education		
Less than 5th Grade	Ref	Ref
5th - 8th Completed	1.04	1.01 - 1.07
Greater than 8th Completed	1.57	1.53 - 1.62
Year of Diagnosis		
2015	Ref	Ref
2016	1.03	1.00 - 1.06
2017	0.95	0.93 - 0.98
Comorbidities		
HIV Positive	0.33	0.32 - 0.34
Alcohol Use Disorder	0.55	0.54 - 0.57
Diabetes	1.04	1.00 - 1.08
Mental Health Condition	0.73	0.69 - 0.78
Tuberculosis Form		
Pulmonary	Ref	Ref
Extrapulmonary	1.06	1.02 - 1.09
Extrapulmonary and Pulmonary	0.79	0.74 - 0.84

¹ aOR = Adjusted odds ratio

² Incarceration*DOT indicates the use of an interaction term

367

368 **Table 3. Factors associated with treatment success among incarcerated individuals in a**
 369 **multivariable logistic regression model**

	aOR ¹	95% CI
Directly Observed Therapy	2.50	2.31 - 2.71
Male sex	1.23	1.01-1.49
Age, years		
18-25	Ref	Ref
26-45	1.10	1.01 - 1.19
46-65	0.97	0.81 - 1.14
> 65	0.46	0.33 - 0.65
Self-Identified Race		
white	Ref	Ref
black	0.83	0.72 - 0.94
Asian	0.69	0.45 - 1.05
brown/mixed Race	0.75	0.69 - 0.82
indigenous	0.49	0.29 - 0.82
Education		
Less than 5th Grade	Ref	Ref
5th - 8th Completed	1.31	1.20 - 1.44
Greater than 8th Completed	1.77	1.58 - 1.97
Year of Diagnosis		
2015	Ref	Ref
2016	1.06	0.96 - 1.18
2017	1.02	0.93 - 1.13
Comorbidities		
HIV Positive	0.39	0.34 - 0.45
Alcohol Use Disorder	0.63	0.57 - 0.70
Diabetes	0.97	0.72 - 1.30
Mental Health Condition	0.60	0.46 - 0.80
Tuberculosis Form		
Pulmonary	Ref	Ref
Extrapulmonary	0.80	0.66 - 0.97
Extrapulmonary and Pulmonary	0.58	0.42 - 0.80

370

¹ aOR = adjusted odds ratio

371

372 **Figure Legends:**

373

374 **Figure 1. Predicted Probabilities of Treatment Success Among Incarcerated Individuals**
375 **from the Incarcerated Multivariable Model Stratified by DOT Status.** Facets indicate risk
376 factors, points indicate mean predicted probability of treatment success, whiskers indicate
377 interquartile ranges, and color indicates DOT treatment status.


378

379 **Figure 2. Percentage of the Incarcerated Tuberculosis Patients without DOT by State from**
380 **2015 to 2017.** Darker colors indicate an increasing percentage of incarcerated tuberculosis
381 patients without DOT.

382

383

384 **Figure 1**
385



386
387
388

389 **Figure 2**
390

